143 related articles for article (PubMed ID: 27448671)
1. Association of erythropoiesis-stimulating agents and the incidence risk of cancer diagnosis among chronic dialysis patients: a nested case-control study.
René É; Lazrak HH; Laurin LP; Elftouh N; Vallée M; Lafrance JP
Nephrol Dial Transplant; 2017 Jun; 32(6):1047-1052. PubMed ID: 27448671
[TBL] [Abstract][Full Text] [Related]
2. Types of erythropoiesis-stimulating agents and risk of end-stage kidney disease and death in patients with non-dialysis chronic kidney disease.
Minutolo R; Garofalo C; Chiodini P; Aucella F; Del Vecchio L; Locatelli F; Scaglione F; De Nicola L
Nephrol Dial Transplant; 2021 Jan; 36(2):267-274. PubMed ID: 32829405
[TBL] [Abstract][Full Text] [Related]
3. Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease.
Seliger SL; Zhang AD; Weir MR; Walker L; Hsu VD; Parsa A; Diamantidis CJ; Fink JC
Kidney Int; 2011 Aug; 80(3):288-94. PubMed ID: 21389972
[TBL] [Abstract][Full Text] [Related]
4. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients.
Kalantar-Zadeh K; Lee GH; Miller JE; Streja E; Jing J; Robertson JA; Kovesdy CP
Am J Kidney Dis; 2009 May; 53(5):823-34. PubMed ID: 19339087
[TBL] [Abstract][Full Text] [Related]
5. Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter.
Nordstrom BL; Luo W; Fraeman K; Whyte JL; Nordyke RJ
J Manag Care Pharm; 2008; 14(9):858-69. PubMed ID: 19006442
[TBL] [Abstract][Full Text] [Related]
6. Use of Erythropoietin-Stimulating Agents (ESA) in Patients With End-Stage Renal Failure Decided to Forego Dialysis: Palliative Perspective.
Cheng HW; Chan KY; Lau HT; Man CW; Cheng SC; Lam C
Am J Hosp Palliat Care; 2017 May; 34(4):380-384. PubMed ID: 26718957
[TBL] [Abstract][Full Text] [Related]
7. Comparative Effectiveness of Iron and Erythropoiesis-Stimulating Agent Dosing on Health-Related Quality of Life in Patients Receiving Hemodialysis.
Freburger JK; Ellis AR; Wang L; Butler AM; Kshirsagar AV; Winkelmayer WC; Brookhart MA
Am J Kidney Dis; 2016 Feb; 67(2):271-82. PubMed ID: 26508682
[TBL] [Abstract][Full Text] [Related]
8. Erythropoiesis-stimulating agents: dose and mortality risk.
Bellinghieri G; Condemi CG; Saitta S; Trifirò G; Gangemi S; Savica V; Buemi M; Santoro D
J Ren Nutr; 2015 Mar; 25(2):164-8. PubMed ID: 25529282
[TBL] [Abstract][Full Text] [Related]
9. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease.
Carrero JJ; Bárány P; Yilmaz MI; Qureshi AR; Sonmez A; Heimbürger O; Ozgurtas T; Yenicesu M; Lindholm B; Stenvinkel P
Nephrol Dial Transplant; 2012 Feb; 27(2):709-15. PubMed ID: 21617198
[TBL] [Abstract][Full Text] [Related]
10. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis.
Koulouridis I; Alfayez M; Trikalinos TA; Balk EM; Jaber BL
Am J Kidney Dis; 2013 Jan; 61(1):44-56. PubMed ID: 22921639
[TBL] [Abstract][Full Text] [Related]
11. Characterizing hospitalizations of end-stage renal disease patients on dialysis and inpatient utilization of erythropoiesis-stimulating agent therapy.
Brophy DF; Daniel G; Gitlin M; Mayne TJ
Ann Pharmacother; 2010 Jan; 44(1):43-9. PubMed ID: 20028955
[TBL] [Abstract][Full Text] [Related]
12. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
13. Impact of pharmacist-managed erythropoiesis-stimulating agents clinics for patients with non-dialysis-dependent CKD.
Aspinall SL; Cunningham FE; Zhao X; Boresi JS; Tonnu-Mihara IQ; Smith KJ; Stone RA; Good CB;
Am J Kidney Dis; 2012 Sep; 60(3):371-9. PubMed ID: 22633556
[TBL] [Abstract][Full Text] [Related]
14. Erythropoiesis stimulating agents and anaemia of end-stage renal disease.
Schmid H; Schiffl H
Cardiovasc Hematol Agents Med Chem; 2010 Jul; 8(3):164-72. PubMed ID: 20443766
[TBL] [Abstract][Full Text] [Related]
15. Early response to erythropoiesis-stimulating agents in non-dialysis chronic kidney disease patients.
Kuwahara M; Arai Y; Takehara E; Sasaki Y; Yoshimine T; Kusaka K; Shikuma S; Akita W; Uchida S
Clin Exp Nephrol; 2016 Aug; 20(4):585-594. PubMed ID: 26511877
[TBL] [Abstract][Full Text] [Related]
16. Time savings of weekly versus three-times-per-week administration of erythropoiesis stimulating agents in United States dialysis patients.
Stephens JM; Emerson LC; Spry LA; Caloyeras JP; Anderson ER; Reitan JF; Ashfaq A
Curr Med Res Opin; 2016; 32(2):313-20. PubMed ID: 26583202
[TBL] [Abstract][Full Text] [Related]
17. Erythropoiesis-stimulating agent dosing, haemoglobin and ferritin levels in UK haemodialysis patients 2005-13.
Birnie K; Caskey F; Ben-Shlomo Y; Sterne JA; Gilg J; Nitsch D; Tomson C
Nephrol Dial Transplant; 2017 Apr; 32(4):692-698. PubMed ID: 27190350
[TBL] [Abstract][Full Text] [Related]
18. Hyporesponsiveness to erythropoiesis-stimulating agents and renal survival in non-dialysis CKD patients.
Minutolo R; Conte G; Cianciaruso B; Bellizzi V; Camocardi A; De Paola L; De Nicola L
Nephrol Dial Transplant; 2012 Jul; 27(7):2880-6. PubMed ID: 22319218
[TBL] [Abstract][Full Text] [Related]
19. Frequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patients.
Hahn D; Cody JD; Hodson EM
Cochrane Database Syst Rev; 2014 May; 2014(5):CD003895. PubMed ID: 24872328
[TBL] [Abstract][Full Text] [Related]
20. Trends in anemia care in older patients approaching end-stage renal disease in the United States (1995-2010).
Winkelmayer WC; Mitani AA; Goldstein BA; Brookhart MA; Chertow GM
JAMA Intern Med; 2014 May; 174(5):699-707. PubMed ID: 24589911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
